CHGCY

Chugai Pharmaceutical Co., Ltd. [CHGCY] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?

CHGCY Stock Summary

Top 10 Correlated ETFs

CHGCY

Top 10 Correlated Stocks

CHGCY

In the News

CHGCY Financial details

Company Rating

Market Cap

54.49B

Income

325.47B

Revenue

1111.37B

Book val./share

Cash/share

Dividend

Dividend %

Employees

7.6K

Optionable

Shortable

Yes

Earnings

25 Apr 2024

P/E

27.05

Forward P/E

PEG

-20.66

P/S

7.14

P/B

5.93

P/C

P/FCF

47.77

Quick Ratio

3.54

Current Ratio

4.76

Debt / Equity

LT Debt / Equity

EPS (TTM)

197.83

EPS next Y

EPS next Q

EPS this Y

-13.1%

EPS next Y

EPS next 5Y

EPS last 5Y

15.57%

Revenue last 5Y

10.12%

Revenue Q/Q

6.17%

EPS Q/Q

17.56%

SMA20

-4.55%

SMA50

-8.7%

SMA100

-22.22%

Inst Own

Inst Trans

ROA

19%

ROE

23%

ROC

0.3%

Gross Margin

58%

Oper. Margin

37%

Profit Margin

26%

Payout

39%

Shs Outstand

Shs Float

Target Price

52W Range

11.93-22.61

52W High

-5.68%

52W Low

+88.64%

RSI

Rel Volume

0.18

Avg Volume

154.08K

Volume

27.18K

Perf Week

-3.4%

Perf Month

-6.32%

Perf Quarter

-21.79%

Perf Half Y

-21.96%

Beta

0.469

Volatility

0.49%, 0.5%

Prev Close

1.17%

Price

20.75

Change

0.39%

Something similar

Top by Market Cap

Top Correlated ETFs

Top Correlated Stocks

Similar Market Cap

Company Profile

Volume Average 154.08K
Market Capitalization 54.49B
Employee 7.6K
CEO Dr. Osamu Okuda
Headquarters Tokyo,JP
IPO Date 2012-08-03
Website https://www.chugai-pharm.co.jp

Chugai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, manufacturing, sale, importation, and exportation of pharmaceuticals in Japan and internationally. The company's products for oncology primarily include Avastin, Tecentriq, Perjeta, Alecensa, Herceptin, Kadcyla, Rituxan, Gazyva, and Xeloda; osteoporosis, including Actemra, Edirol, and Bonviva; renal diseases consist of Mircera and Oxarol; and neurology/other diseases comprise Hemlibra, CellCept, and Enspryng. It has various development product candidates in the areas of oncology, bone and joint diseases, autoimmune diseases, renal diseases, neurology, and other diseases. Chugai Pharmaceutical Co., Ltd. has strategic alliances with Roche Group; and collaboration and joint research with academia. The company was founded in 1925 and is headquartered in Tokyo, Japan. Chugai Pharmaceutical Co., Ltd. is a subsidiary of Roche Holding Ltd.